iifl-logo-icon 1

Dr Reddys Laboratories Ltd Share Price

6,835
(1.72%)
Jul 15, 2024|01:49:59 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open6,750
  • Day's High6,884.95
  • 52 Wk High6,745
  • Prev. Close6,719.45
  • Day's Low6,702.55
  • 52 Wk Low5,076.25
  • Turnover (lac)31,100.61
  • P/E26.17
  • Face Value5
  • Book Value1,458.97
  • EPS256.8
  • Mkt. Cap (Cr.)1,14,028.1
  • Div. Yield0.59
Loading...
  • Open6,662.7
  • Day's High6,794.8
  • Spot6,852.9
  • Prev. Close6,637.3
  • Day's Low6,637.2
  • ViewLong BuildUp
  • Market Lot125
  • OI(Chg %)92,250 (3.01%)
  • Roll Over%0.49
  • Roll Cost0.81
  • Traded Vol.8,13,125 (-13.17%)
View More Futures

Dr Reddys Laboratories Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

6,750

Prev. Close

6,719.45

Turnover(Lac.)

31,100.61

Day's High

6,884.95

Day's Low

6,702.55

52 Week's High

6,745

52 Week's Low

5,076.25

Book Value

1,458.97

Face Value

5

Mkt Cap (₹ Cr.)

1,14,028.1

P/E

26.17

EPS

256.8

Divi. Yield

0.59

Dr Reddys Laboratories Ltd Corporate Action

22 Mar 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

10 May 2023

12:00 AM

BookCloser

arrow

10 May 2023

12:00 AM

Dividend

Dividend Amount: 40

arrow

10 May 2023

12:00 AM

AGM

Announcement Date: 10 May, 2023

arrow

Dr Reddys Laboratories Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Dr Reddys Laboratories Ltd SHAREHOLDING SNAPSHOT

15 Jul, 2024|02:14 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 26.65%

Foreign: 0.00%

Indian: 26.65%

Non-Promoter- 62.79%

Institutions: 62.79%

Non-Institutions: 10.37%

Custodian: 0.17%

Share Price

Dr Reddys Laboratories Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

-15.7

-43.6

-76.9

-113.5

Preference Capital

0

0

0

0

Reserves

24,256.5

20,517.8

18,413.1

17,097.2

Net Worth

24,240.8

20,474.2

18,336.2

16,983.7

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

14,405.2

13,349.1

11,850.4

9,359.3

yoy growth (%)

7.91

12.64

26.61

-3.7

Raw materials

-5,045.9

-4,123

-3,573.8

-2,631

As % of sales

35.02

30.88

30.15

28.11

Employee costs

-2,434.6

-2,270.1

-2,030.2

-1,843

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

2,223.8

3,056.2

2,775.8

696.99

Depreciation

-814.3

-835

-789.2

-774.1

Tax paid

-600.6

-869.8

161.9

-130.1

Working capital

1,395.8

1,078.3

508.8

-170.1

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

7.91

12.64

26.61

-3.7

Op profit growth

-17.3

9.31

115.77

-23.81

EBIT growth

-27.1

9.89

271.62

-52.56

Net profit growth

-25.75

-25.57

418.2

-59.04

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

27,916.4

24,587.9

21,439.1

18,972.2

17,460

Excise Duty

0

0

0

0

0

Net Sales

27,916.4

24,587.9

21,439.1

18,972.2

17,460

Other Operating Income

94.7

81.8

106.1

75.3

57

Other Income

909

1,092.5

554.7

339.4

676.7

Dr Reddys Laboratories Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,577.3

124.083,78,675.04867.60.865,536.9998.75

Cipla Ltd

CIPLA

1,512.05

32.871,22,092.681,038.40.563,444.92346.41

Divis Laboratories Ltd

DIVISLAB

4,539.3

76.441,20,480.265310.662,259507.93

Zydus Lifesciences Ltd

ZYDUSLIFE

1,175.15

34.281,18,217.41,405.20.263,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,719.45

26.171,12,137.091,034.80.595,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Dr Reddys Laboratories Ltd

Management

Register Office

Registrar Office

Co-Chairman & Managing Directo

G V Prasad

Executive Chairman

K Satish Reddy

Independent Director

Kalpana Morparia

Independent Director

Shikha Sanjaya Sharma

Independent Director

Leo Puri

Independent Director

K P Krishnan

Independent Director

Pennv Wan

Company Sec. & Compli. Officer

K Randhir Singh

Independent Director

Arun M. Kumar

Independent Director

Claudio Albrecht

Independent Director

Sanjiv Mehta

Independent Director

Alpna Seth

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Dr Reddys Laboratories Ltd (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services &Active Ingredients, Global Generics and Proprietary Products - Dr. Reddys offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations. The companys major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddys operates in markets across the globe. Its major markets include - USA, India, Russia & CIS countries, and Europe.Dr Reddys Laboratories was incorporated in the year 1984 in Hyderabad. The company was established by Dr Anji Reddy with an initial capital outlay of Rs 25 lakh. The company made their beginning with the manufacture of Active Pharmaceutical Ingredients and Intermediates (API) and commenced operations with a single drug in a 60-tonne facility near Hyderabad, India. In the year 1986, the company shares were listed on the Bombay Stock Exchange. Also, they entered international market with exports of Methyldopa.In the year 1987, the company obtained first USFDA approval for Ibuprofen API. In the year 1988, they acquired Benzex Laboratories Pvt Ltd to expand their Bulk Actives business. In the year 1990, they exported Norfloxacin and Ciprofloxacin to Europe
Read More

Company FAQs

What is the Dr Reddys Laboratories Ltd share price today?

Down Arrow

The Dr Reddys Laboratories Ltd shares price on N/A is Rs.₹6828.95 today.

What is the Market Cap of Dr Reddys Laboratories Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Dr Reddys Laboratories Ltd is ₹113927.17 Cr. as of 15 Jul ‘24

What is the PE and PB ratio of Dr Reddys Laboratories Ltd?

Down Arrow

The PE and PB ratios of Dr Reddys Laboratories Ltd is 26.17 and 4.61 as of 15 Jul ‘24

What is the 52 Week High and Low of Dr Reddys Laboratories Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Dr Reddys Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Dr Reddys Laboratories Ltd is ₹5077.7 and ₹6741.9 as of 15 Jul ‘24

What is the CAGR of Dr Reddys Laboratories Ltd?

Down Arrow

Dr Reddys Laboratories Ltd's CAGR for 5 Years at 20.64%, 3 Years at 6.98%, 1 Year at 29.55%, 6 Month at 18.13%, 3 Month at 10.47% and 1 Month at 10.86%.

What is the shareholding pattern of Dr Reddys Laboratories Ltd?

Down Arrow

The shareholding pattern of Dr Reddys Laboratories Ltd is as follows:
Promoters - 26.65 %
Institutions - 62.80 %
Public - 10.38 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.